Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Anthem Inc. CORP UNIT 050118
ANTX | US
2.98
USD-0.03
-1.00%
ANTX | US
About Anthem Inc. CORP UNIT 050118
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
2.98
Open
3.01
High
3.11
Low
2.94
AN2 Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing treatments for rare chronic and serious infectious diseases. It is developing epetraborole which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park California.
View LessANTX | US
Risk
75.6
Sharpe
1.10
Luna's Score
40/100
Recommendation
Sell
Luna says (ANTX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
55.3%1 month
75.6%3 months
236.5%6 months
175.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.32
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-2.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
88.93M
MarketCap(USD)
88.93M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-69.48
Short ratio
0.75
Short perc.
0.98
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.78
Range1M
2.29
Range3M
5.91
Volumes: Market Activity
Rel. volume
1.47
Price X volume
1.67M
